<DOC>
	<DOCNO>NCT02289703</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( study way drug enters leave blood tissue time ) pharmacodynamics ( way drug may change body function ) single 15-milligram ( mg ) dose rivaroxaban healthy participant creatinine clearance ( CLcr ) great equal ( &gt; = ) 80 milliliter per minute ( mL/min ) clinically stable participant end-stage renal disease ( ESRD ) maintenance hemodialysis ( method use remove waste material blood kidney unable ) .</brief_summary>
	<brief_title>A Pharmacokinetics , Pharmacodynamics Safety Study Single Dose Rivaroxaban Participants With End-Stage Renal Disease ( ESRD ) Maintenance Hemodialysis</brief_title>
	<detailed_description>This open-label ( participant researcher aware treatment , participant receive ) , single-dose , single-center , parallel group ( medical research study compare response 2 group participant receive different intervention ) study . This study consist Screening Period ( within 21 day prior admission study center Day -1 ) , follow 2 treatment period ESRD participant ( Group A ) ( Treatment Period 1 : rivaroxaban administer 2 hour start 4-hour hemodialysis session Day 1 ; Treatment Period 2 : rivaroxaban administer 3 hour completion 4-hour hemodialysis session Day 1 ) , 1 treatment period healthy participant ( Group B ) ( single oral dose rivaroxaban administer Day 1 ) . Each treatment period duration 4 day . For ESRD participant , 2 treatment period separate washout period least 7 day maximum 14 day . The total study duration ESRD participant approximately 43 day . The total study duration healthy participant approximately 25 day . Blood sample collect assess pharmacokinetic pharmacodynamic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>A . All Participants : Body mass index ( BMI = weight kilogram [ kg ] divide square height meter [ ] ) 18 38 kg/m^2 , extremes include , body weight less 50 kg B . Additional Inclusion Criteria ESRD Participants ( Group A ) : Participants endstage renal disease ( ESRD ) require maintenance hemodialysis 2 3 time week least 3 month prior Screening Participants clinically stable medical condition , consistent ESRD , judge investigator basis Screening physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) , result clinical laboratory test perform within 3 week first administration study drug ( unless judge clinically unimportant investigator sponsor ) Participants diastolic blood pressure le ( &lt; ) 110 millimeter mercury ( mmHg ) and/or systolic blood pressure &lt; 180 mmHg ( Screening ) record 5 minute rest sit position C. Additional Inclusion Criteria Healthy Matched Control Participants ( Group B ) : Healthy Participants basis Screening physical examination , medical history , vital sign , 12lead ECG , result clinical laboratory test perform within 3 week prior administration study drug Participants diastolic blood pressure &lt; 95 mmHg and/or systolic blood pressure &lt; 150 mmHg record 5 minute rest sit position Participants normal renal function characterize creatinine clearance ( CLcr ) &gt; 80 mL/min CockcroftGault estimate Participants history clinically significant medical illness prior Screening include ( limited ) chronic atrial fibrillation , hemodynamically significant valvular heart disease , heart failure ( New York Heart Association Class &gt; =II ) within 6 month prior Screening visit , cardiac revascularization within 6 month include percutaneous transluminal coronary angioplasty coronary artery bypass graft surgery , ischemic stroke within 6 month , previous intracranial hemorrhage time , anemia hemoglobin concentration &lt; 9 gram per deciliter ( g/dL ) , illness investigator considers exclude participant could interfere interpretation study result Participants diagnose current malignancy/active disease ; ( however , participant clinically stable prostate cancer , basal cell carcinoma skin require antineoplastic treatment previous cancer least one year eligible ) Participants psychiatric disorder would impair participant 's ability participate complete study opinion investigator sponsor Participants history gastrointestinal disease ( example , Crohn 's disease ) could result impaired absorption study drug Participants disease condition could influence physiological metabolic turnover study drug ( example , endocrine disease , febrile condition , severe infection ) Participants history significant hemorrhage gastrointestinal ulceration within 6 month prior screen visit Participants know primary coagulation disorder ( example , von Willebrand 's disease , hemophilia ) Participants history recurrent dialysis membrane thrombosis Participants sensitivity heparin Participants dialysis acute renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>Healthy</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>BAY 59-7939</keyword>
	<keyword>JNJ-39039039</keyword>
	<keyword>Xarelto</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Blood Coagulation</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>